Quantib Brain 1.2 cleared for U.S. market

The upgrade of Quantib Brain is cleared by the U.S. Food and Drug Administration (FDA). Quantib Brain 1.2 enables comparison of multiple MRI exams of the same patient. This longitudinal analysis will quantify volume differences in brain tissues and white matter hyperintensities. Exams are displayed side-by-side and white matter hyperintensities are automatically labeled as consistent, new or disappearing.